Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan ; volume:38 ; number:1 ; day:24 ; month:9 ; year:2019 ; pages:69-84 ; date:1.2020
PharmacoEconomics ; 38, Heft 1 (24.9.2019), 69-84, 1.2020
- Creator
-
Hernandez, Luis
Kuwabara, Hiroyo
Shah, Anshul
Yamabe, Kaoru
Burnett, Heather
Fahrbach, Kyle
Koufopoulou, Maria
Iwakiri, Ryuichi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40273-019-00841-1
- URN
-
urn:nbn:de:101:1-2020041920133627514672
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hernandez, Luis
- Kuwabara, Hiroyo
- Shah, Anshul
- Yamabe, Kaoru
- Burnett, Heather
- Fahrbach, Kyle
- Koufopoulou, Maria
- Iwakiri, Ryuichi
- SpringerLink (Online service)
Other Objects (12)
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
Efficacy and safety of Vedolizumab in patients with inflammatory bowel disease in association with Vedolizumab drug levels
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
Efficacy and safety of Vedolizumab in patients with inflammatory bowel disease in association with Vedolizumab drug levels
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
Efficacy and safety of Vedolizumab in patients with inflammatory bowel disease in association with Vedolizumab drug levels
Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort